|
|
 |
|
Viewing report
|
|
|
|
Company Financials: ARCA Biopharma, Inc.
Datamonitor, Jan 2010
The Company Financials offers insights into the financial performance of the company over last five years for about 1000 leading global companies. The datapack covers wealth of financial information relating to income statement, balance sheet, and cash flow statements. .
Scope
- Contains five years data on income statement, balance sheet, cash flows and other financials in the reported currency and its US Dollar translation
- Provides key ratios
- Includes information on revenue distribution by business segments and geographies
Highlights of this title
ARCA biopharma (ARCA), formerly Nuvelo, is a biopharmaceutical company focused on developing genetically-targeted therapies for heart failure and other cardiovascular diseases.
ARCA's lead product candidate Gencaro (bucindolol hydrochloride), a beta-blocker and mild vasodilator is under review by the US Food and Drug Administration (FDA), for chronic heart failure (HF).
Key reasons to purchase this title
- Access important financial information and analysis on the company in a single datapack
- Understand the financial evolution of the company over the last five years
- Build the periodic assessment of the company's performance for five year adjusted financial data along with key ratios and market capitalization
Customers who bought this item also bought
Company Financials: Array Biopharma Inc.
Company Financials: Edwards Lifesciences Corporation
Company Financials: Labopharm Inc.
Company Financials: Bristol-Myers Squibb Company
Company Financials: Eli Lilly and Company
Company Financials: Arqule, Inc.
Company Financials: Biogen Idec, Inc.
Company Financials: Becton, Dickinson and Company
Company Financials: Genzyme Corporation
Company Financials: Hologic, Inc.
|
|
|
|
